LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CEO Justin Schreiber sold 25,000 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.52, for a total value of $163,000.00. Following the completion of the transaction, the chief executive officer now owns 2,728,715 shares in the company, valued at approximately $17,791,221.80. The trade was a 0.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
LifeMD Stock Performance
Shares of LifeMD stock opened at $6.04 on Thursday. The company's fifty day simple moving average is $5.19 and its 200-day simple moving average is $5.98. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $12.88. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC lifted its stake in shares of LifeMD by 311.7% during the 3rd quarter. Barclays PLC now owns 49,017 shares of the company's stock valued at $257,000 after buying an additional 37,112 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of LifeMD by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company's stock valued at $4,293,000 after buying an additional 83,598 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of LifeMD by 306.8% during the 3rd quarter. XTX Topco Ltd now owns 55,738 shares of the company's stock valued at $292,000 after buying an additional 42,037 shares in the last quarter. State Street Corp lifted its stake in shares of LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company's stock valued at $6,055,000 after buying an additional 192,861 shares in the last quarter. Finally, Centiva Capital LP purchased a new position in shares of LifeMD during the 3rd quarter valued at $196,000. Hedge funds and other institutional investors own 35.52% of the company's stock.
Analyst Upgrades and Downgrades
Trump’s Secret Manhattan Project
From Banyan Hill Publishing | Ad
On January 20, a whole new Manhattan Project is set to begin:
Trump’s Manhattan Project.
Folks, I just spent six months investigating this...and what I found is shocking.
Click here and I’ll show you exactly how to position your money
A number of equities research analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of LifeMD in a report on Monday, November 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. Mizuho began coverage on shares of LifeMD in a research note on Wednesday. They set a "neutral" rating and a $7.00 target price for the company. Finally, B. Riley initiated coverage on shares of LifeMD in a research report on Friday, August 23rd. They set a "buy" rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $11.50.
Get Our Latest Report on LFMD
LifeMD Company Profile
(
Get Free Report)
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
